Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) General Information
Description
Worldwide license and commercialization rights to autologous anti-cd19 t-cell therapy product located in Tianjin City, China. The asset is widely expressed during all phases of b-cell development and a validated target for b-cell driven hematological malignancies in children and adults with relapsed B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Contact Information
Corporate Office
- Building 5, No.8, Haitai Development 3rd Avenue
- Huayuan Industrial Zone
- Tianjin
- China
Corporate Office
- Building 5, No.8, Haitai Development 3rd Avenue
- Huayuan Industrial Zone
- Tianjin
- China
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) FAQs
-
Where is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) headquartered?
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) is headquartered in Tianjin, China.
-
What industry is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) in?
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)’s primary industry is Buildings and Property.
-
Is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) a private or public company?
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) is a Private company.
-
What is Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)’s current revenue?
The current revenue for Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) is .
-
Who are Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)’s investors?
Juventas (Drug Discovery) has invested in Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China).
-
When was Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) acquired?
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) was acquired on 03-Dec-2019.
-
Who acquired Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China)?
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) was acquired by CASI Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process